Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Pasi A, Janne"'
Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study
Autor:
Leou Ismael Banla, MD, PhD, Alice Tzeng, MD, PhD, John P. Baillieul, Melin J. Kandekhar, MD, PhD, Kelly J. Fitzgerald, MD, PhD, Jaclyn LoPiccolo, MD, PhD, Holly A. Poitras, Daniel E. Soto, MD, Julia K. Rotow, MD, Lisa Singer, MD, PhD, Henning Willers, MD, David E. Kozono, MD, PhD, Pasi A. Janne, MD, PhD, Raymond H. Mak, MD, Zofia Piotrowska, MD, Florence K. Keane, MD, Benjamin H. Kann, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 10, Pp 100559- (2023)
Introduction: Thoracic radiotherapy (TRT) is increasingly used in patients receiving osimertinib for advanced NSCLC, and the risk of pneumonitis is not established. We investigated the risk of pneumonitis and potential risk factors in this population
Externí odkaz:
https://doaj.org/article/9087b5cf562e48d1adfa693c2233ecf6
Autor:
Biagio Ricciuti, Arielle Elkrief, Joao Alessi, Xinan Wang, Yvonne Li, Hersh Gupta, Daniel M. Muldoon, Arrien A. Bertram, Federica Pecci, Giuseppe Lamberti, Alessandro Di Federico, Adriana Barrichello, Victor R. Vaz, Malini Gandhi, Elinton Lee, Geoffrey I. Shapiro, Hyesun Park, Mizuki Nishino, James Lindsay, Kristen D. Felt, Bijaya Sharma, Andrew D. Cherniack, Scott Rodig, Daniel R. Gomez, Narek Shaverdian, Mehrdad Rakaee, Chaitanya Bandlamudi, Marc Ladanyi, Pasi A. Janne, Adam J. Schoenfeld, Lynette M. Sholl, Mark M. Awad, Michael L. Cheng
Publikováno v:
Clinical Cancer Research. :OF1-OF11
Purpose: ATM is the most commonly mutated DNA damage and repair gene in non–small cell lung cancer (NSCLC); however, limited characterization has been pursued. Experimental Design: Clinicopathologic, genomic, and treatment data were collected for 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62451ff0a5df3fbff60cb7bb3f125bba
https://doi.org/10.1158/1078-0432.ccr-22-3413
https://doi.org/10.1158/1078-0432.ccr-22-3413
Autor:
Michael L. Cheng, Mark M. Awad, Lynette M. Sholl, Adam J. Schoenfeld, Pasi A. Janne, Marc Ladanyi, Chaitanya Bandlamudi, Mehrdad Rakaee, Narek Shaverdian, Daniel R. Gomez, Scott Rodig, Andrew D. Cherniack, Bijaya Sharma, Kristen D. Felt, James Lindsay, Mizuki Nishino, Hyesun Park, Geoffrey I. Shapiro, Elinton Lee, Malini Gandhi, Victor R. Vaz, Adriana Barrichello, Alessandro Di Federico, Giuseppe Lamberti, Federica Pecci, Arrien A. Bertram, Daniel M. Muldoon, Hersh Gupta, Yvonne Li, Xinan Wang, Joao Alessi, Arielle Elkrief, Biagio Ricciuti
Supplementary Figure 8. Oncoprint plot showing the distribution of the most commonly mutated genes in NSCLCs with complete ATM loss by IHC (ATMLOST), intact ATM expression (ATMINTACT), and ATM heterogeneous loss (ATMHET LOST) by IHC.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13741cbb04662f96d405a375d90c5505
https://doi.org/10.1158/1078-0432.22893749.v1
https://doi.org/10.1158/1078-0432.22893749.v1
Autor:
Michael L. Cheng, Mark M. Awad, Lynette M. Sholl, Adam J. Schoenfeld, Pasi A. Janne, Marc Ladanyi, Chaitanya Bandlamudi, Mehrdad Rakaee, Narek Shaverdian, Daniel R. Gomez, Scott Rodig, Andrew D. Cherniack, Bijaya Sharma, Kristen D. Felt, James Lindsay, Mizuki Nishino, Hyesun Park, Geoffrey I. Shapiro, Elinton Lee, Malini Gandhi, Victor R. Vaz, Adriana Barrichello, Alessandro Di Federico, Giuseppe Lamberti, Federica Pecci, Arrien A. Bertram, Daniel M. Muldoon, Hersh Gupta, Yvonne Li, Xinan Wang, Joao Alessi, Arielle Elkrief, Biagio Ricciuti
Supplementary Figure 25. (A) Intratumoral, (B) tumor-stroma interface, and (C) total CD8+ PD1+ T cells according to ATM/TP53 co-mutation status. (D) Intratumoral, (E) tumor-stroma interface, and (F) total FOXP3+ immune cells according to ATM/TP53 co-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4832d06f698c197f62e7460f193ac73b
https://doi.org/10.1158/1078-0432.22893785.v1
https://doi.org/10.1158/1078-0432.22893785.v1
Autor:
Michael L. Cheng, Mark M. Awad, Lynette M. Sholl, Adam J. Schoenfeld, Pasi A. Janne, Marc Ladanyi, Chaitanya Bandlamudi, Mehrdad Rakaee, Narek Shaverdian, Daniel R. Gomez, Scott Rodig, Andrew D. Cherniack, Bijaya Sharma, Kristen D. Felt, James Lindsay, Mizuki Nishino, Hyesun Park, Geoffrey I. Shapiro, Elinton Lee, Malini Gandhi, Victor R. Vaz, Adriana Barrichello, Alessandro Di Federico, Giuseppe Lamberti, Federica Pecci, Arrien A. Bertram, Daniel M. Muldoon, Hersh Gupta, Yvonne Li, Xinan Wang, Joao Alessi, Arielle Elkrief, Biagio Ricciuti
Supplementary Table 6. Baseline clinicopathologic features of patients with ATM mutated NSCLC according ATM protein expression by immunohistochemistry.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::176b7c37c8fec33f686792d0b436c628
https://doi.org/10.1158/1078-0432.22893725.v1
https://doi.org/10.1158/1078-0432.22893725.v1
Autor:
Michael L. Cheng, Mark M. Awad, Lynette M. Sholl, Adam J. Schoenfeld, Pasi A. Janne, Marc Ladanyi, Chaitanya Bandlamudi, Mehrdad Rakaee, Narek Shaverdian, Daniel R. Gomez, Scott Rodig, Andrew D. Cherniack, Bijaya Sharma, Kristen D. Felt, James Lindsay, Mizuki Nishino, Hyesun Park, Geoffrey I. Shapiro, Elinton Lee, Malini Gandhi, Victor R. Vaz, Adriana Barrichello, Alessandro Di Federico, Giuseppe Lamberti, Federica Pecci, Arrien A. Bertram, Daniel M. Muldoon, Hersh Gupta, Yvonne Li, Xinan Wang, Joao Alessi, Arielle Elkrief, Biagio Ricciuti
Supplementary Figure 15. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to chemo-immunotherapy among patients with advanced/metastatic PD-L1 negative (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99671e01949b911609d65415e3ae10e1
https://doi.org/10.1158/1078-0432.22893821.v1
https://doi.org/10.1158/1078-0432.22893821.v1
Autor:
Michael L. Cheng, Mark M. Awad, Lynette M. Sholl, Adam J. Schoenfeld, Pasi A. Janne, Marc Ladanyi, Chaitanya Bandlamudi, Mehrdad Rakaee, Narek Shaverdian, Daniel R. Gomez, Scott Rodig, Andrew D. Cherniack, Bijaya Sharma, Kristen D. Felt, James Lindsay, Mizuki Nishino, Hyesun Park, Geoffrey I. Shapiro, Elinton Lee, Malini Gandhi, Victor R. Vaz, Adriana Barrichello, Alessandro Di Federico, Giuseppe Lamberti, Federica Pecci, Arrien A. Bertram, Daniel M. Muldoon, Hersh Gupta, Yvonne Li, Xinan Wang, Joao Alessi, Arielle Elkrief, Biagio Ricciuti
Purpose:ATM is the most commonly mutated DNA damage and repair gene in non–small cell lung cancer (NSCLC); however, limited characterization has been pursued.Experimental Design:Clinicopathologic, genomic, and treatment data were collected for 5,17
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14fb9154f461f03d3fc78526062a7b50
https://doi.org/10.1158/1078-0432.c.6651170
https://doi.org/10.1158/1078-0432.c.6651170
Autor:
Michael L. Cheng, Mark M. Awad, Lynette M. Sholl, Adam J. Schoenfeld, Pasi A. Janne, Marc Ladanyi, Chaitanya Bandlamudi, Mehrdad Rakaee, Narek Shaverdian, Daniel R. Gomez, Scott Rodig, Andrew D. Cherniack, Bijaya Sharma, Kristen D. Felt, James Lindsay, Mizuki Nishino, Hyesun Park, Geoffrey I. Shapiro, Elinton Lee, Malini Gandhi, Victor R. Vaz, Adriana Barrichello, Alessandro Di Federico, Giuseppe Lamberti, Federica Pecci, Arrien A. Bertram, Daniel M. Muldoon, Hersh Gupta, Yvonne Li, Xinan Wang, Joao Alessi, Arielle Elkrief, Biagio Ricciuti
Supplementary Table 1. Baseline clinicopathologic features of the 5172 patients with NSCLC which underwent comprehensive tumor genomic profiling at the Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1765f5f2eebb2aa8a7e3eff5127b7a9b
https://doi.org/10.1158/1078-0432.22893743.v1
https://doi.org/10.1158/1078-0432.22893743.v1
Autor:
Michael L. Cheng, Mark M. Awad, Lynette M. Sholl, Adam J. Schoenfeld, Pasi A. Janne, Marc Ladanyi, Chaitanya Bandlamudi, Mehrdad Rakaee, Narek Shaverdian, Daniel R. Gomez, Scott Rodig, Andrew D. Cherniack, Bijaya Sharma, Kristen D. Felt, James Lindsay, Mizuki Nishino, Hyesun Park, Geoffrey I. Shapiro, Elinton Lee, Malini Gandhi, Victor R. Vaz, Adriana Barrichello, Alessandro Di Federico, Giuseppe Lamberti, Federica Pecci, Arrien A. Bertram, Daniel M. Muldoon, Hersh Gupta, Yvonne Li, Xinan Wang, Joao Alessi, Arielle Elkrief, Biagio Ricciuti
Supplementary Figure 6. (A) Tumor mutational burden and (B) PD-L1 tumor proportion score distributions according to ATM protein expression by IHC (lost versus intact).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa50afd5954655038009daf445fa7a5d
https://doi.org/10.1158/1078-0432.22893758
https://doi.org/10.1158/1078-0432.22893758
Autor:
Michael L. Cheng, Mark M. Awad, Lynette M. Sholl, Adam J. Schoenfeld, Pasi A. Janne, Marc Ladanyi, Chaitanya Bandlamudi, Mehrdad Rakaee, Narek Shaverdian, Daniel R. Gomez, Scott Rodig, Andrew D. Cherniack, Bijaya Sharma, Kristen D. Felt, James Lindsay, Mizuki Nishino, Hyesun Park, Geoffrey I. Shapiro, Elinton Lee, Malini Gandhi, Victor R. Vaz, Adriana Barrichello, Alessandro Di Federico, Giuseppe Lamberti, Federica Pecci, Arrien A. Bertram, Daniel M. Muldoon, Hersh Gupta, Yvonne Li, Xinan Wang, Joao Alessi, Arielle Elkrief, Biagio Ricciuti
Supplementary Figure 9. (A) Disease free- and overall survival among patients with (A) stage I, and (B) stage II NSCLC according to ATM mutation status.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c5124168d093e7206f580d564ca9913
https://doi.org/10.1158/1078-0432.22893746
https://doi.org/10.1158/1078-0432.22893746